|
|
|
|
| LEADER |
00000nam a2200000 a 4500 |
| 001 |
1694199 |
| 003 |
ICU |
| 005 |
20221018200831.2 |
| 008 |
941220s1995 paua b 001 0 eng c |
| 010 |
|
|
|a 94040512
|
| 020 |
|
|
|a 0397514166
|
| 035 |
|
|
|a (ICU)BID19460194
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d OrLoB-B
|d OCoLC
|
| 041 |
0 |
|
|a eng
|
| 050 |
1 |
0 |
|a RC271.B53
|b B55 1995
|
| 060 |
|
0 |
|a QZ 266 B6145 1995
|
| 082 |
0 |
0 |
|a 616.99/406
|2 20
|
| 245 |
0 |
0 |
|a Biologic therapy of cancer /
|c edited by Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg ; with 115 contributors.
|
| 250 |
|
|
|a 2nd ed.
|
| 260 |
|
|
|a Philadelphia :
|b Lippincott,
|c c1995.
|
| 300 |
|
|
|a xvii, 919 p. :
|b ill. (some col.) ;
|c 29 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g Pt. 1.
|t Principles of Biologic Therapy of Cancer.
|g 1.
|t Biology of Cellular Immune Responses /
|r Nicholas P. Restifo and John R. Wunderlich.
|g 2.
|t Biology of Antibody-Mediated Responses /
|r Sandra J. Smith-Gill.
|g 3.
|t Biology of Tumor Antigens.
|g Sect. 3.1.
|t Genes Coding for Tumor Antigens Recognized by T Lymphocytes /
|r Yutaka Kawakami and Paul F. Robbins.
|g Sect. 3.2.
|t Tumor Antigens Recognized by Immune Cells /
|r Walter J. Storkus and Michael T. Lotze.
|g Sect. 3.3.
|t Tumor Antigens Recognized by Monoclonal Antibodies /
|r Soldano Ferrone, T. Ming Chu, Ingegerd Hellstrom and Karl E. Hellstrom.
|g 4.
|t Biology of Cytokines: The Interleukins /
|r Robert J. Tushinski and James J. Mule.
|g 5.
|t Principles of Cell Killing by Biologic Agents /
|r David M. Hockenbery.
|g 6.
|t Immunocompetence and Cancer /
|r Israel Penn --
|g Pt. 2.
|t Biologic Therapy of Cancer.
|g 7.
|t Colony-Stimulating Factors: Basic Principles and Preclinical Studies /
|r Malcolm A. S. Moore.
|g 8.
|t Colony-Stimulating Factors: Clinical Applications.
|g Sect. 8.1.
|t Granulocyte-Stimulating Factors /
|r Langdon L. Miller.
|g Sect. 8.2.
|t Platelet-Stimulating Factors /
|r Jeffrey S. Weber and Michael S. Gordon.
|g Sect. 8.3.
|t Erythrocyte-Stimulating Factors /
|r Robert T. Means, Jr.
|g Sect. 8.4.
|t Macrophage-Colony Stimulating Factor /
|r David R. Parkinson.
|g 9.
|t Biologic Therapy with Interleukin-2: Preclinical Studies /
|r Michael T. Lotze.
|g 10.
|t Biologic Therapy with Interleukin-2: Clinical Applications.
|g Sect. 10.1.
|t Principles of Administration and Management of Side Effects /
|r Douglas J. Schwartzentruber.
|g Sect. 10.2.
|t Melanoma /
|r Francesco M. Marincola and Steven A. Rosenberg.
|g Sect. 10.3.
|t Renal Cell Cancer /
|r James C. Yang.
|g Sect. 10.4.
|t Other Cancers /
|r Mario Sznol.
|g 11.
|t Role of IL-4, IL-6, and IL-12 in Cancer Therapy /
|r Robert L. Truitt, Carolyn A. Keever and Ernest C. Borden.
|g 12.
|t Biologic Therapy with TNF: Preclinical Studies /
|r Walter Fiers.
|g 13.
|t Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion /
|r Douglas L. Fraker, H. Richard Alexander and Harvey I. Pass.
|g 14.
|t Biologic Therapy with Interferon-[alpha] and [beta]: Preclinical Studies /
|r Thazepadath Sreevalsan.
|g 15.
|t Biologic Therapy with Interferon-[alpha] and [beta]: Clinical Applications.
|g Sect. 15.1.
|t Hairy Cell Leukemia, Chronic Myelogenous Leukemia, and Myeloproliferative Disorders /
|r Kenneth A. Foon.
|g Sect. 15.2.
|t Renal Cell Cancer /
|r Paul D. Savage and Hyman B. Muss.
|g Sect. 15.3.
|t Melanoma /
|r John M. Kirkwood.
|g Sect. 15.4.
|t Kaposi's Sarcoma /
|r Susan E. Krown.
|g Sect. 15.5.
|t Multiple Myeloma /
|r Sydney E. Salmon.
|g Sect. 15.6.
|t Clinical Applications of Interferon in Other Tumors /
|r William J. John and Kenneth A. Foon.
|g 16.
|t Biologic Therapy with Interferon-[gamma] /
|r Jorge R. Quesada.
|g 17.
|t Combination Cytokine Therapy /
|r Michael B. Atkins, Elizabeth G. Trehu and James W. Mier.
|g 18.
|t Cell Transfer Therapy: Preclinical Studies /
|r Suzanne L. Topalian.
|g 19.
|t Cell Transfer Therapy: Clinical Applications /
|r Steven A. Rosenberg.
|g 20.
|t Monoclonal Antibodies in Cancer Therapy.
|g Sect. 20.1.
|t Basic Principles /
|r Jeffrey Schlom.
|g Sect. 20.2.
|t Immunotoxins and Recombinant Toxins /
|r Lee H. Pai and Ira Pastan.
|g Sect. 20.3.
|t Radioisotope Conjugates /
|r Steven M. Larson, George Sgouros and Nai-Kong V. Cheung.
|g 21.
|t Clinical Applications of Monoclonal Antibodies in Cancer.
|g Sect. 21.1.
|t B-Cell Lymphomas /
|r Larry W. Kwak, Michael L. Grossbard and Walter J. Urba.
|g Sect. 21.2.
|t T-Cell Leukemia/Lymphoma /
|r Thomas A. Waldmann.
|g Sect. 21.3.
|t Melanoma /
|r Alan N. Houghton and Paul B. Chapman.
|g Sect. 21.4.
|t Adenocarcinomas /
|r Ernest C. Borden and Tom Anderson.
|g Sect. 21.5.
|t Purging of Bone Marrow /
|r John G. Gribben and Lee M. Nadler.
|g Sect. 21.6.
|t Antibodies to Growth Factors and Receptors /
|r John Mendelsohn and Jose Baselga.
|g 22.
|t Cancer Vaccines: Preclinical Studies /
|r Dorothee Herlyn, Lutz Jacob and Rajasekharan Somasundaram.
|g 23.
|t Cancer Vaccines: Clinical Applications.
|g Sect. 23.1.
|t Immune Adjuvants /
|r Emmanuel T. Akporiaye and Evan M. Hersh.
|g Sect. 23.2.
|t Whole Cell Vaccines /
|r Michael J. Mastrangelo, Henry C. Maguire, Jr., Edmund C. Lattime and David Berd.
|g Sect. 23.3.
|t Viral Oncolysates /
|r Muthukumaran Sivanandham and Marc K. Wallack.
|g Sect. 23.4.
|t Partially Purified Tumor Antigen Vaccines /
|r Jean-Claude Bystryn, Richard L. Shapiro and Ruth Oratz.
|g Sect. 23.5.
|t Immunization with Synthetic or Highly Purified Tumor Antigens /
|r Philip Livingston.
|g 24.
|t Local Therapy with Biologic Agents.
|g Sect. 24.1.
|t Intralesional Therapy /
|r Donald L. Morton and Andreas Barth.
|g Sect. 24.2.
|t Instillation Therapy for Bladder Cancer /
|r Harry W. Herr.
|g 25.
|t Gene Therapy of Cancer.
|g Sect. 25.1.
|t Basic Principles and Safety Considerations /
|r Paul Tolstoshev and W. French Anderson.
|g Sect. 25.2.
|t Gene Therapy Using Lymphocyte Modification /
|r Patrick Hwu and Steven A. Rosenberg.
|g Sect. 25.3.
|t Gene Therapy Using Stem Cell Modification /
|r Albert Deisseroth, Siqing Fu, Elie G. Hanania, Moshe Talpaz, Hagop Kantarjian and Richard Champlin.
|g Sect. 25.4.
|t Gene Therapy Using "Suicide" Genes /
|r R. Michael Blaese.
|g Sect. 25.5.
|t Gene Therapy by Direct Gene Transfer /
|r Gary J. Nabel and Elizabeth G. Nabel.
|g Sect. 25.6.
|t Antisense Oligodeoxynucleotides /
|r Cy A. Stein.
|g Sect. 25.7.
|t Gene Modification of Tumors /
|r Elizabeth M. Jaffee, Herb Hurwitz and Drew M. Pardoll --
|g Pt. 3.
|t Other Approaches to Biologic Therapy.
|g 26.
|t Chemically Defined Immunomodulators and Interferon Inducers /
|r Patricia L. Witt.
|g 27.
|t Levamisole /
|r David R. Parkinson.
|g 28.
|t Differentiation Agents /
|r Raymond P. Warrell, Jr.
|g 29.
|t Tamoxifen /
|r John R. Benson, Michael Baum and Anthony A. Colletta.
|g 30.
|t Systemic Activation of Macrophages by Liposomes Containing Immunomodulators /
|r Eugenie S. Kleinerman and Isaiah J. Fidler.
|g 31.
|t Thymosin /
|r Karen Kashmanian Oates and Allan L. Goldstein.
|g 32.
|t Antimetastatic Therapy /
|r Ronald H. Goldfarb and Kenneth W. Brunson.
|g 33.
|t Interaction of Biologic Agents with Chemotherapy /
|r Jose Baselga and John Mendelsohn --
|g Pt. 4.
|t Regulatory Issues Related to Biologic Agents.
|g 34.
|t Development of Biological Therapeutics for Oncologic Use /
|r Jay P. Siegel, Theresa Gerrard, Joy A. Cavagnaro, Patricia Keegan, Roger B. Cohen and Kathryn Zoon.
|
| 650 |
|
0 |
|a Biological response modifiers
|x Therapeutic use.
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|0 http://id.loc.gov/authorities/subjects/sh87002642
|
| 650 |
|
0 |
|a Cancer
|x Gene therapy.
|0 http://id.loc.gov/authorities/subjects/sh92005201
|
| 650 |
1 |
2 |
|a Neoplasms
|x therapy.
|
| 650 |
2 |
2 |
|a Biological Response Modifiers
|x therapeutic use.
|
| 650 |
2 |
2 |
|a Biological Response Modifiers
|x immunology.
|
| 650 |
|
7 |
|a Biological response modifiers
|x Therapeutic use.
|2 fast
|0 http://id.worldcat.org/fast/fst00832315
|
| 650 |
|
7 |
|a Cancer
|x Gene therapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00845367
|
| 650 |
|
7 |
|a Cancer
|x Immunotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00845386
|
| 700 |
1 |
|
|a DeVita, Vincent T.,
|c Jr.,
|d 1935-
|1 http://viaf.org/viaf/14848102
|
| 700 |
1 |
|
|a Hellman, Samuel.
|0 http://id.loc.gov/authorities/names/n81031868
|1 http://viaf.org/viaf/56686755
|
| 700 |
1 |
|
|a Rosenberg, Steven A.
|0 http://id.loc.gov/authorities/names/n79097023
|1 http://viaf.org/viaf/315224699
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 035 |
|
|
|a (OCoLC)31378441
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i c02d3dc4-402c-53ec-aea7-2b9d8cc64494
|s ddee5219-3987-5c47-804e-f412e36d48b1
|
| 928 |
|
|
|t Library of Congress classification
|a RC271.B53B550 1995
|l JCL
|c JCL-Sci
|i 2284809
|
| 927 |
|
|
|t Library of Congress classification
|a RC271.B53B550 1995
|l JCL
|c JCL-Sci
|e CRERAR
|b 42445741
|i 3190259
|
